Free Trial
NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

$80.60
+1.93 (+2.45%)
(As of 07/26/2024 ET)
Today's Range
$78.77
$81.27
50-Day Range
$71.24
$83.81
52-Week Range
$51.79
$85.95
Volume
969,063 shs
Average Volume
1.07 million shs
Market Capitalization
$12.70 billion
P/E Ratio
63.97
Dividend Yield
0.40%
Price Target
$81.00

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
0.5% Upside
$81.00 Price Target
Short Interest
Healthy
2.39% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.74
Upright™ Environmental Score
News Sentiment
0.51mentions of Bio-Techne in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.38%
From $1.56 to $1.80 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

86th out of 936 stocks

Biological Products, Except Diagnostic Industry

9th out of 154 stocks

TECH stock logo

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

TECH Stock News Headlines

Bio-Techne Corporation (TECH)
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Demystifying Bio-Techne: Insights From 4 Analyst Reviews
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Ex-Dividend for 5/24 Dividend
5/10/2024
Dividend Payable
5/24/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/07/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,050
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$81.00
High Stock Price Target
$95.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$285.26 million
Pretax Margin
20.13%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.61 per share
Book Value
$12.49 per share

Miscellaneous

Free Float
150,572,000
Market Cap
$12.70 billion
Optionable
Optionable
Beta
1.29

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

TECH Stock Analysis - Frequently Asked Questions

How have TECH shares performed this year?

Bio-Techne's stock was trading at $77.16 on January 1st, 2024. Since then, TECH shares have increased by 4.5% and is now trading at $80.60.
View the best growth stocks for 2024 here
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The firm's quarterly revenue was up 3.2% on a year-over-year basis.

When did Bio-Techne's stock split?

Shares of Bio-Techne split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly minted shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Does Bio-Techne have any subsidiaries?

Bio-Techne subsidiaries include these companies: MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and others.

Who are Bio-Techne's major shareholders?

Bio-Techne's top institutional shareholders include Bank of New York Mellon Corp (1.72%), Sumitomo Mitsui Trust Holdings Inc. (1.09%), Allspring Global Investments Holdings LLC (0.68%) and Raymond James & Associates (0.22%). Insiders that own company stock include Charles R Kummeth, Roeland Nusse, Brenda S Furlow, Robert V Baumgartner, John L Higgins, Norman David Eansor, James Hippel and Kim Kelderman.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT) and Cisco Systems (CSCO).

This page (NASDAQ:TECH) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners